How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Sell
21
DRIO Quote, Financials, Valuation and Earnings
Last price:
$0.68
Seasonality move
:
-4.41%
Day range:
$0.66 - $0.77
52-week range:
$0.65 - $2.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.08x
P/B ratio:
0.40x
Volume:
356K
Avg. volume:
150.7K
1-year change:
-60.38%
Market cap:
$23.6M
Revenue:
$20.4M
EPS (TTM):
-$0.94
Analysts' Opinion
-
Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, DarioHealth has an estimated upside of 404.76% from its current price of $0.69.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.69.
Fair Value
-
According to the consensus of 3 analysts, DarioHealth has 404.76% upside to fair value with a price target of -- per share.
DRIO vs. S&P 500
-
Over the past 5 trading days, DarioHealth has overperformed the S&P 500 by 4.79% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
DarioHealth does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
DarioHealth has grown year-over-year revenues for 2 quarters straight. In the most recent quarter DarioHealth reported revenues of $7.4M.
Earnings Growth
-
DarioHealth has grown year-over-year earnings for 0 quarters straight. In the most recent quarter DarioHealth reported earnings per share of -$0.25.
Enterprise value:
37M
EV / Invested capital:
0.42x
Price / LTM sales:
1.08x
EV / EBIT:
--
EV / Revenue:
1.60x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.94x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.2M
Return On Assets:
-41.44%
Net Income Margin (TTM):
-205.62%
Return On Equity:
-71.65%
Return On Invested Capital:
-49.97%
Operating Margin:
-162.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $26.9M | $23.5M | $23.1M | $3.5M | $7.4M | |
| Gross Profit | $7.5M | $8.6M | $9.2M | $610K | $3.9M | |
| Operating Income | -$69.5M | -$51M | -$60.3M | -$15.5M | -$12M | |
| EBITDA | -$65.1M | -$49.6M | -$56.9M | -$14.3M | -$9.9M | |
| Diluted EPS | -$1.73 | -$2.04 | -$0.94 | -$0.49 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $39.8M | $59.2M | $71.6M | $56.2M | $29.5M | |
| Total Assets | $41.1M | $117.2M | $126.3M | $106.5M | $110M | |
| Current Liabilities | $5.9M | $12.7M | $11.5M | $8.1M | $18.8M | |
| Total Liabilities | $6.1M | $12.7M | $37.4M | $38.5M | $51.4M | |
| Total Equity | $35M | $104.4M | $88.9M | $68M | $58.5M | |
| Total Debt | -- | -- | $24M | $29M | $28.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$55M | -$31M | -$39.2M | -$8.6M | -$7.4M | |
| Cash From Investing | -$958K | -$523K | -$9M | -$281K | -$32K | |
| Cash From Financing | $61.7M | $18.5M | $20.2M | $204K | -- | |
| Free Cash Flow | -$55.6M | -$31.5M | -$39.4M | -$8.9M | -$7.4M | |
DRIO
Sector
Market Cap
$23.6M
$46.1M
Price % of 52-Week High
26.67%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-60.38%
-30.52%
Beta (5-Year)
1.468
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.71
200-day SMA
Sell
Level
$1.13
Bollinger Bands (100)
Sell
Level
0.77 - 0.99
Chaikin Money Flow
Buy
Level
33.5M
20-day SMA
Sell
Level
$0.73
Relative Strength Index (RSI14)
Sell
Level
43.74
ADX Line
Buy
Level
16.6
Williams %R
Neutral
Level
-75.8889
50-day SMA
Sell
Level
$0.83
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Sell
Level
-68.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.7281)
Sell
CA Score
(Annual)
Level (-2.2279)
Buy
Beneish M-Score
(Annual)
Level (-4.3943)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4388)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Stock Forecast FAQ
In the current month, DRIO has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DRIO average analyst price target in the past 3 months is --.
-
Where Will DarioHealth Stock Be In 1 Year?
According to analysts, the consensus estimate is that DarioHealth share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About DarioHealth?
Analysts are divided on their view about DarioHealth share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that DarioHealth is a Sell and believe this share price will drop from its current level to --.
-
What Is DarioHealth's Price Target?
The price target for DarioHealth over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DRIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for DarioHealth is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DRIO?
You can purchase shares of DarioHealth via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase DarioHealth shares.
-
What Is The DarioHealth Share Price Today?
DarioHealth was last trading at $0.68 per share. This represents the most recent stock quote for DarioHealth. Yesterday, DarioHealth closed at $0.69 per share.
-
How To Buy DarioHealth Stock Online?
In order to purchase DarioHealth stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 49.62% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is up 10.88% over the past day.
